Active	Status	Sponsor type	Region	Phase	Filter
5 Active 7 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Mego, Michal
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer	Recruiting	3	6000	Europe, Canada, Japan, US, RoW	Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane	Eli Lilly and Company	Breast Neoplasms	10/27	03/32
PEACE6-Unfit, NCT04916613 / 2020-003663-26: ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)	Recruiting	3	300	Europe	Darolutamide 300 mg, Nubeqa®, Placebo, Androgen deprivation therapy, ADT	UNICANCER, Bayer	Prostate Cancer Metastatic	03/28	09/37
DISGCT, NCT03950830: Disulfiram and Cisplatin in Refractory TGCTs.	Completed	2	12	Europe	Disulfiram, Antabus	National Cancer Institute, Slovakia	Germ Cell Tumor	09/21	01/22
NCT04265274: Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.	Withdrawn	2	28	Europe	Disulfiram, Antabus, Vinorelbin, Navelbine, Cisplatin, Copper	National Cancer Institute, Slovakia	Metastatic Breast Cancer	01/22	01/23
SCTMICROBIOM, NCT04691284: Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation	Recruiting	N/A	100	Europe	Blood, urine and stool sampling	National Cancer Institute, Slovakia, Slovak Academy of Sciences	Hematologic Neoplasms	12/23	12/24